MedPath

A randomized multi-center phase II study on the efficacy of postoperative Rikkunshito plus Elental in gastric cancer patients with adjuvant chemotherapy

Phase 2
Conditions
Gastric cancer
Registration Number
JPRN-UMIN000032845
Lead Sponsor
PO corporation Digestive Disorder Support Organization (DDSO)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

1) Patients with another malignant neoplasm 2) Patients who received preoperative chemo- or radiotherapy 3) Patients with preoperative malnutrition (alb less than 3.0g per dl) 4) Patients who were administrated Kanpo 5) Patients with allergy of ELENTAL 6) Patients with history of Kanpo allergy 7) Patients with severe psychiatric disorder 8) Patients who was considered ineligible by the investigator

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
change rate of mascle mass 6 months after intervention
Secondary Outcome Measures
NameTimeMethod
change rate of body weight and fat mass 6 months after intervention nutrition index compliance of adjuvant chemotherapy drug safty
© Copyright 2025. All Rights Reserved by MedPath